FRX Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 14, 2022.

Detailed results of the vote for the election of directors are set out below:

Name of Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Dr. Khalid Islam	15,884,541	99.59%	65,032	0.41%
Mr. Adrian Haigh	15,884,387	99.59%	65,186	0.41%
Mr. Chris A. Rallis	15,883,822	99.59%	65,751	0.41%
Mr. Marco Brughera	15,886,739	99.61%	62,837	0.39%
Dr. Jodi Cook	15,887,034	99.61%	62,539	0.39%
Mr. Rostislav Raykov	15,884,175	99.59%	65,398	0.41%

Shareholders voted 99.23% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 99.03% in favour of the compensation paid to the Company’s named executive officers.

For further information, please contact:

Rosty RaykovChief Executive OfficerFennec Pharmaceuticals Inc.T: (919) 636-5144